Bifogade filer
Warrants of series TO10B were subscribed to approximately 34.1 percent and iZafe Group AB receives approximately SEK 3.14 million
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
iZafe Group AB (publ.) (”iZafe” or the ”Company”) today announces the outcome of the exercise of warrants of series TO10B, which were issued during the fourth quarter of 2021. In total, 12,072,688 warrants of series TO10B were exercised, corresponding to approximately 34.1 percent of the total number of outstanding warrants of series TO10B, for subscription of 12,072,688 B-shares at a subscription price of SEK 0.26 per B-share. iZafe will receive approximately SEK 3.14 million before issuing costs through the exercise of the warrants of series TO10B.
Background
The subscription period for exercise of the warrants of series TO10B took place from September 27, 2022, up to and including October 11, 2022. The subscription price per B-share for exercising the warrants of series TO10B was set to SEK 0.26.
In total, 12,072,688 warrants of series TO10B were exercised for subscription of 12,072,688 B-shares, meaning that approximately 34.1 percent of all outstanding warrants of series TO10B were exercised for subscription of B-shares.
Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to B-shares within approximately three (3) weeks.
Number of shares, share capital and dilution
Through the exercise of the warrants of series TO10B, the number of shares in iZafe increases by 12,072,688 B-shares, from 70,874,308 shares (consisting of 600,000 A-shares och 70,274,308
B-shares) to a total of 82,946,996 shares. The share capital will increase by SEK 2,414,537.60 from SEK 14,174,861.60 to SEK 16,589,399.20.
For existing shareholders who did not exercise any warrants of series TO10B, the dilution amounts to approximately 14.6 percent of the number of shares and approximately 13.7 percent of the number of votes in the Company.
Advisors
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of the warrants of series TO10B.